Genmab — November 2019

[E_L]

The first couple of indications prostate and lung have not confirmed the hypothesis. But we still feel there's merit to continue that work in the other indications. Several of them are hematologic malignancies, for example, where the tumor microenvironment is very different than solid tumors. And so we'll see those studies to their end. They're small signal seeking studies to test the hypothesis.

[E_L]

We've said from the beginning, it's a low probability of success, but we feel that the data -- the preclinical data from our own labs and from the medical community merits that we test the hypothesis in a lean way that would help to determine whether there is a broader opportunity for CD38 antibodies like isatuximab that have unique properties due to the epitope that we target relative to other competitors.

[E_L]

Q: I noticed early you brought another CD38 into development. That's quite a long way behind both isatuximab and Darzalex.

[E_L]

A: Indeed, we did put a next-generation CD38 into the clinic. The rationale behind these next, wave of CD38 antibodies is to ask the question of whether they can rescue patients who have failed a frontline CD38 standard of care antibody.

[E_L]

We've engineered into these molecules enhanced properties that enable them to recruit immune cells to attack the malignancy in a more amplified way. The first of those has recently gone in the clinic.

[E_L]

We have another one coming along behind that that uses yet another immune mechanism. What we know so far about mechanisms of resistance to the standard of care CD38 antibodies, is that the levels of CD38 on the myeloma cell are reduced.

[E_L]

But CD38 still remains on the myeloma cell, however at lower levels. So the target is still relevant. And we feel there's sufficient retained expression for most patients that we can still go at that target but with these enhanced antibodies. So there would really be an attempt to rescue patients who failed a frontline standard care agent.

[Sukkeralf]

Genmab then nedds to speed up HexaBody CD38 so that they are not that far behind Sanofi

[bibob]

I'am sure they work hard with that.

[Helge_LarsenPI-redaktør]

Ses vi? https://www.proinvestor.com/debat/78610

[Bulder]

They have the money for it, so it shouldn't be a problem to speed it up a bit. And thx again E L.

[E_L]

a small new trial using BMS-986253 / HuMax-IL8 for NSCLC https://clinicaltrials.gov/ct2/show/NCT04123379

[Bella1]

Børsen nede 11.06?

[Bella1]

Fondsbørsen, forstås...

[Bulder]

følg med i chat nyheder

[Solsen]

Hvis ikke de åbner når vi ikke ATH og festen i dag...

[bikube]

Børsen åbner igen kl. 13.

[E_L]

a saw from this message from a Belgian University hospital that one of the area's BMS-986253 is used is Dermatological tumors/ melanoma https://www.uzgent.be/nl/zorgaanbod/mdspecialismen/Geneesmiddelenonderzoek/Lopende-studies/Paginas/Indicatoren-dermatologische-tumoren.aspx (clinicaltrials only mentioned 'advanced cancers' https://www.clinicaltrials.gov/ct2/show/study/NCT03400332?term=BMS-986253&show_locs=Y#locn )

[Plimsoller]

Så er de vist oppe igen. Kursen hoppede lige.

[Bulder]

allerede nyt børsstop